Engineering IL-12 for tumor specific cytotoxicity results in enhanced therapeutic window

Time: 2:30 pm


  • Multiple attenuating components help to mask IL-12 off-tumor mediated cytotoxicity
  • Tumor specific activation of IL12-Fc elicits a potent anti-tumor activity in xenograft models
  • No dose limiting toxicity observed in cynomolgus monkeys at levels well above expected therapeutic doses